Sanofi: new approval for Sarclisa in Japan
(CercleFinance.com) - Sanofi announces that the Japanese Ministry of Health has approved its Sarclisa, in combination with bortezomib, lenalidomine and dexamethasone (VRd regimen), for the treatment of newly diagnosed multiple myeloma (MMND) in adults.
This approval is based on the positive results of the Phase III IMROZ study, which demonstrated that this combination significantly improved progression-free survival compared with the VRd regimen only in patients not eligible for transplantation.
It thus offers MMND patients access to new therapeutic options. In Japan, Sarclisa was launched in August 2020 and approved in combination with four different treatment regimens.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
This approval is based on the positive results of the Phase III IMROZ study, which demonstrated that this combination significantly improved progression-free survival compared with the VRd regimen only in patients not eligible for transplantation.
It thus offers MMND patients access to new therapeutic options. In Japan, Sarclisa was launched in August 2020 and approved in combination with four different treatment regimens.
Copyright (c) 2025 CercleFinance.com. All rights reserved.